Journal
AMERICAN JOURNAL OF TRANSPLANTATION
Volume 7, Issue 8, Pages 1968-1973Publisher
WILEY
DOI: 10.1111/j.1600-6143.2007.01885.x
Keywords
acute rejection; B cells; CD20; renal biopsy; renal transplantation
Categories
Ask authors/readers for more resources
We examined rejection outcome and graft survival in 58 adult patients with acute cellular rejection Banff type I (ARI) or II (ARII), within 1 year after transplantation, with or without CD20-positive infiltrates. Antibody-mediated rejection was not examined. Of the 74 allograft biopsies, performed from 1999 to 2001, 40 biopsies showed ARI and 34 biopsies showed ARII; 30% of all the biopsies showed CD20-positive clusters with more than 100 cells, 9% with more than 200 cells and 5% with more than 275 cells. Patients with B cell-rich (> 100 or > 200/HPF CD20-positive cells) and B cell-poor biopsies (< 50 CD20-positive cells/HPF) were compared. Serum creatinine and eGFR of B cell-rich (CD20 > 100/HPF) and B cell-poor were not significantly different at rejection, or at 1, 3, 6 and 12 months, and during additional 3 years follow-up after rejection, although higher creatinine at 1 year was noted in the > 200/HPF group. Graft survival was also not different between B cell-rich and B cell-poor groups (p = 0.8 for > 100/HPF, p = 0.9 for > 200/HPF CD20-positive cells). Our data do not support association of B cell-rich infiltrates in allograft biopsies and worse outcome in acute rejection type I or II, but do not exclude the possible contribution of B cells to allograft rejection.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available